Jenkins John Kenneth 4

What Happened
Director John K. Jenkins reported a sale of 4,800 shares of Corbus Pharmaceuticals (CRBP) on June 10, 2026. The weighted-average sale price was $7.91 per share (range $7.71–$7.97), for total proceeds of approximately $37,986. This was a sale (not a purchase) and therefore generally viewed as routine insider selling unless tied to other company events.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 11, 2026 (within the normal reporting window).
• Shares sold: 4,800; weighted-average price: $7.91; price range: $7.71–$7.97.
• Proceeds: ~$37,986.
• Holdings after transaction: not specified in the excerpt; filing notes reported holdings include 3,800 unvested RSUs subject to prior vesting schedule (see footnote).
• Notable footnotes: transaction was executed under a Rule 10b5-1 trading plan adopted March 11, 2026; the reported price is a weighted average and detailed per-price breakdown is available on request.

Context
The sale was made under a pre-established 10b5-1 plan, which typically means trades were scheduled in advance and are less indicative of near-term insider sentiment. Sales are common insider activity and, by itself, do not necessarily signal a change in outlook for the company.